Assenagon Asset Management
RCUS icon

Assenagon Asset Management’s Arcus Biosciences RCUS Stock Holding History

Assenagon Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-39,180
Closed -$597K – 1456
2024
Q2 		$597K Sell
39,180
-551
-1% -$8.89K ﹤0.01% 1205
2024
Q1 		$750K Sell
39,731
-7,522
-16% -$130K ﹤0.01% 1114
2023
Q4 		$903K Buy
+47,253
New +$755K ﹤0.01% 1123
2023
Q1 		– Sell
-115,651
Closed -$2.39M – 1491
2022
Q4 		$2.39M Buy
+115,651
New +$3.18M 0.01% 756
2021
Q2 		– Sell
-11,278
Closed -$317K – 1376
2021
Q1 		$317K Sell
11,278
-30,396
-73% -$1.06M ﹤0.01% 1094
2020
Q4 		$1.08M Sell
41,674
-276,613
-87% -$6.7M ﹤0.01% 727
2020
Q3 		$5.46M Buy
318,287
+172,135
+118% +$3.85M 0.03% 310
2020
Q2 		$3.62M Buy
+146,152
New +$3.94M 0.02% 412

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Assenagon Asset Management's RCUS Position: Q3 2024 in Review

Assenagon Asset Management sold out of Arcus Biosciences (RCUS) in Q3 2024, closing a stake of 39,180 shares — an estimated $597K sold.

Assenagon Asset Management first reported a position in RCUS in Q2 2020 and held it in 8 quarters. The position peaked at $5.46M in Q3 2020. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2024.

  • Assenagon Asset Management reported no remaining Arcus Biosciences position as of Q3 2024 after selling out during the quarter.
  • Assenagon Asset Management sold 39,180 Arcus Biosciences shares in Q3 2024, an estimated $597K.
  • Assenagon Asset Management first reported a position in Arcus Biosciences in Q2 2020 and held it in 8 quarters.
  • Assenagon Asset Management's Arcus Biosciences position peaked at $5.46M in Q3 2020.
  • 187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2024.

Based on Assenagon Asset Management's 13F filing for Q3 2024, filed 23 Oct 2024.